{"product_id":"kamada-swot-analysis","title":"Kamada SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eKamada's SWOT snapshot highlights its niche strength in plasma-derived therapeutics, regulatory resilience, and growth opportunities in specialty markets, while flagging supply, R\u0026amp;D intensity, and geographic concentration risks. For investors and strategists seeking actionable conclusions and financial context, the full SWOT delivers a research-backed, editable report. Purchase the complete analysis to plan, pitch, and invest with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized plasma-derived expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKamada’s core competency is in developing and manufacturing plasma-derived protein therapeutics, a technically demanding niche requiring specialized fractionation and purification expertise. Deep process know-how and robust quality systems create high entry barriers and support consistent yields and regulatory compliance across markets. This specialization enables efficient scale-up and rapid tech transfer for new plasma programs, shortening time-to-market and reducing development risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in AATD therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKamada’s focused leadership in Alpha-1 Antitrypsin Deficiency (AATD), a rare disease affecting an estimated ~100,000 severe cases in the US and Europe, builds clinical credibility and payer familiarity following FDA approval of its AAT product in 2014. Post‑marketing data and established physician relationships support adoption, while brand recognition and real-world experience can be leveraged into adjacent respiratory and inflammatory indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified revenue via contract manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eContract manufacturing monetizes Kamada’s excess capacity and plasma expertise, generating recurring fee-based income that smooths revenue cyclicality versus standalone product sales.\u003c\/p\u003e\n\u003cp\u003eCM contracts deepen strategic ties across the plasma ecosystem—suppliers, collectors and drug developers—enhancing cross-selling and long-term demand visibility.\u003c\/p\u003e\n\u003cp\u003eThese services absorb fixed costs and lift asset utilization, improving gross margins and cash flow stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal distribution with partners and direct channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHybrid go-to-market delivers broader geographic reach and payer access through partners while direct channels preserve margins and clinical insight, enabling Kamada to tailor market-entry strategies and tender participation by product and region. Strategic partnerships speed regulatory navigation and tender bids, while direct sales keep close contact with prescribers and patients for lifecycle management. The portfolio mix allows market-specific optimization of pricing, distribution and resource allocation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHybrid GTM: broader reach + payer access\u003c\/li\u003e\n\u003cli\u003ePartnerships: faster market entry, tender capability\u003c\/li\u003e\n\u003cli\u003eDirect channels: margin retention, prescriber\/patient insight\u003c\/li\u003e\n\u003cli\u003ePortfolio-market fit: optimize pricing\/distribution per product\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and quality track record\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOperating in plasma biologics demands strict GMP and blood\/plasma regulation compliance; Kamada holds FDA approval for Glassia and is listed on Nasdaq and TASE, reflecting regulatory credibility. A sustained inspection record and pharmacovigilance reduce approval and supply risks, enabling lifecycle management and label-expansion strategies and strengthening partner confidence for co-marketing and CMO deals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA-approved product: Glassia\u003c\/li\u003e\n\u003cli\u003eDual listing: Nasdaq, TASE\u003c\/li\u003e\n\u003cli\u003eProven inspections + PV systems → lower approval\/supply risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlasma protein therapeutics firm: FDA-cleared product, Nasdaq\/TASE dual listing, AATD focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKamada excels in plasma‑derived protein therapeutics with deep fractionation expertise, FDA approval for Glassia (2014) and dual listing on Nasdaq\/TASE (KMDA), enabling strong regulatory credibility and scalable CMO services. Focused leadership in AATD (~100,000 severe cases US\/EU) and hybrid GTM boost adoption, margins and partner visibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approval\u003c\/td\u003e\n\u003ctd\u003eGlassia, 2014\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eListings\u003c\/td\u003e\n\u003ctd\u003eNasdaq\/TASE (KMDA)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAATD prevalence\u003c\/td\u003e\n\u003ctd\u003e~100,000 severe cases (US\/EU)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Kamada’s internal and external business factors, outlining strengths, weaknesses, opportunities, and threats to map key growth drivers, operational gaps, and market risks shaping the company’s competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a focused SWOT matrix for Kamada that quickly identifies strategic strengths, weaknesses, opportunities and threats to streamline decision-making, align stakeholders, and accelerate action on priority pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarrow therapeutic concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeavy reliance on AATD products concentrates demand and reimbursement risk; in 2024 Kamada's AATD franchise accounted for the bulk of commercial sales, leaving revenue highly sensitive to payer decisions. Any clinical guideline shift or competing therapy could disproportionately cut top-line performance. Limited diversification across indications may slow growth and elevates exposure to single-asset manufacturing disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply dependence on plasma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKamada’s reliance on plasma-derived products ties revenue to stable plasma collection and pricing, with the United States providing roughly 70% of global plasma supply. Donor availability, regulatory constraints and complex logistics have tightened markets in 2022–24, increasing input costs and compressing margins for PDMP manufacturers. Required inventory build and multi-month lead times raise working capital needs and amplify cash flow sensitivity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScale disadvantage versus larger peers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKamada’s smaller scale limits access to donor networks and global distribution compared with leaders such as CSL and Grifols, which together accounted for roughly 40% of plasma capacity in 2024. Higher unit costs and weaker supplier negotiating power raise manufacturing margins versus large peers. Constrained marketing and clinical program budgets reduce commercial reach and can slow market penetration in competitive territories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic and tender exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReliance on select regions and institutional tenders creates revenue lumpiness; losing or delaying tender renewals causes pronounced quarterly volatility, while pricing pressure in public health systems compresses margins and limits profitability. Market entry barriers persist in countries where Kamada lacks local presence, slowing diversification and scale-up.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh tender dependence — revenue timing risk\u003c\/li\u003e\n\u003cli\u003ePublic-system pricing pressure — margin compression\u003c\/li\u003e\n\u003cli\u003eLimited local footprint — barriers to new markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D breadth and pipeline depth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA concentrated R\u0026amp;D portfolio leaves Kamada exposed if lead assets underperform; limited optionality heightens commercial risk. Building pipeline in plasma biologics is capital- and time-intensive—industry 2024 estimates cite $100–300 million and 8–12 years per late-stage program. High clinical costs and rare-patient enrollment (orphan thresholds \u0026lt;200,000) reduce visibility on long-term growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConcentration risk\u003c\/li\u003e\n\u003cli\u003e2024 dev cost est: $100–300M\u003c\/li\u003e\n\u003cli\u003e2024 time to approval est: 8–12 years\u003c\/li\u003e\n\u003cli\u003eOrphan patient scarcity slows trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAATD concentration, plasma reliance (~70%), smaller scale vs peers, costly late-stage R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy AATD concentration (bulk of 2024 commercial sales) heightens payer and guideline risk; limited indication diversification and reliance on plasma (US ~70% supply) raise input-cost exposure. Smaller scale vs CSL\/Grifols (~40% plasma capacity) increases unit costs and tender vulnerability. R\u0026amp;D concentrated; late-stage program cost est $100–300M, 8–12 years.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAATD share\u003c\/td\u003e\n\u003ctd\u003eBulk of commercial sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS plasma supply\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSL+Grifols capacity\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDev cost\u003c\/td\u003e\n\u003ctd\u003e$100–300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime to approval\u003c\/td\u003e\n\u003ctd\u003e8–12 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eKamada SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Kamada SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth, editable version. You’re viewing a live preview of the real file and the complete report becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion of AATD diagnosis and treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImproved screening and genetic testing can expand the treatable AATD pool, given severe AATD prevalence of about 1:2,500–1:5,000 (≈100,000 individuals in US\/EU combined). Physician education and newborn\/adult screening pilots have raised identification from reported 10–20% diagnoses toward higher detection. Earlier diagnosis enables chronic weekly augmentation therapy (≈52 infusions\/year), increasing sustained duration of treatment and driving volume growth in established markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew plasma-derived indications and formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLeveraging Kamada's plasma-platform and FDA approval of Glassia (2018) to develop additional plasma proteins can widen the portfolio and tap rising demand for plasma therapies in 2024. Improved formulations—higher concentration and home-infusion friendly—can boost adherence and reduce administration costs. Expanding indications into inflammatory or infectious diseases diversifies revenue streams. Lifecycle upgrades extend product competitiveness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic penetration and partner alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEntering under-served markets via local distributors accelerates access while avoiding large fixed costs; Kamada, an Israel-based plasma-derived biopharma listed on Nasdaq and TASE, can scale reach rapidly. Co-marketing and licensing deals can unlock regulatory and reimbursement pathways in target countries. Local manufacturing or fill-finish and partner alliances reduce lead times and help secure plasma sourcing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized CMOs in plasma processing benefit from a plasma-derived therapeutics market ~US$32 billion in 2023 with ~6% CAGR to 2028, driving outsourcing demand; winning multi-year contracts boosts utilization and multi-year cash flow visibility for Kamada. Offering analytics and regulatory support raises switching costs; cross-selling CMO clients can convert them into strategic collaborators and recurring-revenue partners.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket: US$32B (2023), ~6% CAGR\u003c\/li\u003e\n\u003cli\u003eMulti-year contracts: improved utilization, multi-year visibility\u003c\/li\u003e\n\u003cli\u003eValue-added services: higher switching costs\u003c\/li\u003e\n\u003cli\u003eCross-selling: convert clients to strategic collaborators\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcess innovation and cost optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcess innovation—yield improvements, chromatography upgrades and digital QC—can materially lower Kamada’s COGS, while better plasma logistics and forecasting cut wastage and stock-outs; automation boosts throughput and regulatory compliance, enabling cost leadership that supports competitive pricing and tender wins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eYield \u0026amp; chromatography: lower COGS\u003c\/li\u003e\n\u003cli\u003eDigital QC: faster releases\u003c\/li\u003e\n\u003cli\u003eLogistics: reduced wastage\/stock-outs\u003c\/li\u003e\n\u003cli\u003eAutomation: higher throughput\/compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAATD diagnoses rise driving treatment demand \u003cstrong\u003eUS$32B\u003c\/strong\u003e plasma backs CMO deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising AATD diagnosis (severe AATD ≈1:2,500–1:5,000 → ~100,000 US\/EU) and expanded screening increase demand for chronic augmentation therapy. Kamada can leverage Glassia FDA approval and plasma platform to broaden plasma-protein portfolio and home-friendly formulations. Outsourcing demand in a ~US$32B (2023) plasma market with ~6% CAGR supports CMO partnerships and multi-year contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlasma market (2023)\u003c\/td\u003e\n\u003ctd\u003eUS$32B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAGR\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSevere AATD prevalence\u003c\/td\u003e\n\u003ctd\u003e1:2,500–1:5,000 (~100,000)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition from large plasma players\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal incumbents operate extensive networks—often exceeding 300 plasma centers—and together capture roughly 60% of the plasma-derived therapies market, giving them scale to undercut prices and tighten tender terms. Their broad portfolios, frequently spanning 150–250 SKUs, enable bundling and preferred-supplier dynamics that can displace Kamada in key markets. This commercial muscle and supply security risk eroding Kamada’s market share and margin pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging non-plasma or gene therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecombinant, RNA and gene‑editing approaches could materially reduce reliance on plasma proteins. Durable or curative options may shrink chronic augmentation demand; AATD prevalence is about 1 in 2,500, concentrating impact. Clinical success in AATD or adjacent indications poses structural risk to Kamada’s plasma‑based portfolio. Payer preference could pivot quickly toward single‑dose gene therapies priced above $1M (eg Zolgensma ~$2.1M).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlasma supply shocks and cost inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory changes, donor shortages or pandemics can sharply cut plasma availability; the US supplies roughly 65–70% of global plasma (2023–24), concentrating supply risk for Kamada.\u003c\/p\u003e\n\u003cp\u003eRising donor compensation and logistics costs have increased collection costs, squeezing margins amid higher pay practices and transport inflation in 2024.\u003c\/p\u003e\n\u003cp\u003eIntensifying competition from large collectors (CSL, Grifols, Takeda expansion) raises procurement risk, and prolonged shortages can force stock-outs and lost sales for plasma-dependent products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and quality compliance risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and quality compliance pose material threats to Kamada: adverse inspection outcomes can lead to warning letters or production halts, pharmacovigilance signals may trigger label restrictions or recalls, compliance costs are persistent and rising, and approval delays can defer product launches and revenue recognition.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdverse inspections: warning letters\/halts\u003c\/li\u003e\n\u003cli\u003ePharmacovigilance: label changes\/recalls\u003c\/li\u003e\n\u003cli\u003eRising compliance costs\u003c\/li\u003e\n\u003cli\u003eApproval delays → deferred revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePayers and public tenders drive recurring price reductions, reference pricing and budget caps across EU and LATAM, pressuring ASPs and compressing realized prices for Kamada. Health technology assessments (HTAs) increasingly require value dossiers and mandatory discounts, limiting access or forcing price concessions. Currency volatility (ILS vs USD\/EUR) — ILS depreciated about 6% vs USD in 2024 — reduces translated ex‑US revenue. Competitive tender wins can raise volumes but often compress margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrice cuts: ongoing in public tenders\u003c\/li\u003e\n\u003cli\u003eHTA-driven discounts: restrict net pricing\u003c\/li\u003e\n\u003cli\u003eFX risk: ILS ≈-6% vs USD in 2024\u003c\/li\u003e\n\u003cli\u003eMargin squeeze: higher volume, lower per-unit price\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated US plasma supply and high-cost gene therapies squeeze margins and volumes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal incumbents (300+ centers, ~60% market share) can undercut Kamada; US supplies ~65–70% of plasma (2023–24), concentrating supply risk. Gene and RNA therapies (single‑dose therapies \u0026gt;$1M; Zolgensma ~$2.1M) could reduce plasma demand. Donor pay and logistics rose in 2024; ILS fell ~6% vs USD, pressuring margins and tenders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncumbents\u003c\/td\u003e\n\u003ctd\u003e300+ centers; ~60% market\u003c\/td\u003e\n\u003ctd\u003ePrice\/tender pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlasma supply\u003c\/td\u003e\n\u003ctd\u003eUS 65–70% (2023–24)\u003c\/td\u003e\n\u003ctd\u003eProcurement risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech risk\u003c\/td\u003e\n\u003ctd\u003eGene therapy \u0026gt;$1M\u003c\/td\u003e\n\u003ctd\u003eVolume decline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX\/costs\u003c\/td\u003e\n\u003ctd\u003eILS -6% (2024)\u003c\/td\u003e\n\u003ctd\u003eMargin squeeze\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098248384860,"sku":"kamada-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/kamada-swot-analysis.png?v=1781798601","url":"https:\/\/pestel-analysis.com\/products\/kamada-swot-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}